PathAI Diagnostics

PathAI Diagnostics is now part of AmeriPath! Our Memphis facility will continue to provide high-quality anatomic pathology and molecular testing services to clients as part of AmeriPath, a Quest Diagnostics company. The PathAI Diagnostics LinkedIn channel will be discontinued on August 30th. Please follow us on the #AmeriPath channel.

PathAI Diagnostics is now part of AmeriPath! Our Memphis facility will continue to provide high-quality anatomic pathology and molecular testing services to clients as part of AmeriPath, a Quest Diagnostics company. Please visit www.AmeriPath.com for more information regarding our services.

It's great to be attending the #SDPA Summer 2024 Meeting in San Diego! Come and visit our booth to learn more about how we can support your dermatology practice now and in the future.

So great to be attending #DDW2024! Visit Booth 1038 to understand how we can support your practice through the combination of sub-specialty pathology expertise and modern tools such as AI.Dx MASH Learn more at: https://lnkd.in/eZJ_xWyw #pathaidiagnostics

Are you attending #DDW2024 in Washington D.C. on May 18th-21st? Come by Booth 1038 to understand how the combination of sub-specialty pathology expertise and modern AI tools can help assist your practice. Learn more at: https://lnkd.in/eZJ_xWyw #pathaidiagnostics

#ICYMI PathAI announced a new multifaceted #partnership with Quest Diagnostics designed to accelerate the adoption of digital and #AI #pathology innovations. https://lnkd.in/e8ES2-mA PathAI continues to operate as an independent entity, offering our services and capabilities to more partners and customers with more flexibility than before.    Here are the key takeaways: 1) Licensing of PathAI’s AISight™ IMS and Algorithm Portfolio  - Quest will license and deploy PathAI's AISight™ #digitalpathology image management system and algorithm portfolio to support their pathology laboratories across the USA. - Significant milestone in the adoption of digital pathology and AI. - Proof of the quality and value of our #data, #development, and #distribution capabilities.   2) Acquisition of PathAI Diagnostics (formerly Poplar Healthcare)  - Quest Diagnostics will acquire select assets of PathAI’s clinical anatomic pathology laboratory business, PathAI Diagnostics (formerly Poplar Healthcare) - PathAI transformed this lab over the past 3 years into a state-of-the-art digitized lab that will serve as Quest’s AI and digital R&D and solutions center. - PathAI will continue to operate as an independent entity, developing digital pathology and AI-powered tools for pathology laboratories and to advance drug development for #biopharma.   3) PathAI Selects Quest as a Preferred Partner for Biopharma Lab Business - PathAI may explore opportunities for mutual support and collaboration in algorithm product menu and IMS evolution. - Product and service enhancements will support all PathAI customers.   PathAI remains committed to accelerating the shift to digital & AI for pathology laboratories and biopharma’s shift towards digitalization.

It was a great #AUA2024 and especially inspiring to be able to talk to dedicated urology healthcare professionals about their challenges and opportunities. In case you missed us, you can learn more about us at: https://lnkd.in/etWNc6Je #pathaidiagnostics

We are excited to be attending #AUA2024 in San Antonio. If you are at the meeting, come and talk to us at Booth 1922 about how we can support your practice and how PathAI Diagnostics is helping to drive digital pathology. Visit www.pathai.com/urology to learn more. #pathaidiagnostics

We are excited to be attending the Florida Society for Histotechnology Meeting. Come and visit our booth to hear more about our comprehensive diagnostic menu and how we can help your practice. #pathaidiagnostics #FSH2024

In our commitment to improving diagnosis of cancer and other diseases, PathAI has formed a multifaceted collaboration with Quest Diagnostics to accelerate the adoption of digital pathology and AI. Together with Quest’s expertise and scale, our collaboration represents a significant milestone for the anatomic pathology industry and marks a major turning point for digital pathology adoption in the U.S. and beyond. Highlights:   · Quest will license PathAI's best-in-class AISight™ IMS and algorithm portfolio to support its pathology laboratories and customer sites in the United States. · Under a separate agreement, Quest will acquire PathAI Diagnostics, which will become Quest’s AI and digital R&D and solutions center in Memphis, Tennessee. · PathAI’s Biopharma Lab, which is separate and distinct from the diagnostic laboratory business, will continue to support its biopharma clients with end-to-end clinical trial services capabilities; Quest will become a preferred partner for PathAI on biopharma collaborations. · Quest and PathAI may explore opportunities to evolve PathAI's algorithm product offering.   PathAI's unique IMS, algorithm portfolio, and digital innovations are reshaping workflow and quality standards at pathology laboratories, helping address customers’ need for more efficient and high-quality pathology operations. Together with our partners, we are dedicated to improving patient outcomes with our AI powered technology and insights.   Read more here. https://lnkd.in/e8ES2-mA #AI #Pathology #AIPoweredPathology #DigitalInnovation #HealthcareInnovation #Progress #Patients